Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
14th Nov 2006, 18:30 GMT
A Sutani, Y Nagai, K Udagawa, Y Uchida, N Koyama, Y Murayama, T Tanaka, H Miyazawa, M Nagata, M Kanazawa, K Hagiwara & K Kobayashi
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp related news:
- Characteristics Of Long-term Lung Cancer Survivors — ScienceDaily Headlines
- NICE disapproves the use of cancer drug Tarceva — The Earth Times Online Newspaper
- Adding Bevacizumab to First-Line Lung Cancer Therapy Shows Potential — Medscape Headlines
- More Patients Asking for Lung Cancer Scans — RedOrbit News - Health
- Lung Carcinogenesis Tracked By DNA Methylation Mapping In Exhaled Breath — ScienceDaily Headlines
- Blocking Cancer-Causing Gene Improves Radiation Effectiveness, Jefferson Researchers Find — Health News from Medical News Today
- [Medical_Sciences] Cis-urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor — Proceedings of the National Academy of Sciences recent issues
- Lung cancer top killer among malignant tumors in Beijing — KeralaNext: China
- Nab-Paclitaxel and Carboplatin Appear Effective in Lung Cancer — Medscape Hematology-Oncology Headlines
- Roswell signs for lung cancer registry — Latest news from Business First of Buffalo
Latest news from British Journal of Cancer AOP:
- Dairy products, calcium and prostate cancer risk
- Stressful life events and cancer risk
- A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
- Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort Study
- Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery
- Perinatal factors, growth and development, and osteosarcoma risk